From Evidence Generation to Market Access: Why Real-Time Data Intelligence Is the Next Frontier for Life Sciences

The conversation about artificial intelligence in pharmaceutical development has matured considerably. A few years ago, AI in this sector meant faster molecule screening or smarter trial design. Today, the discussion is far more nuanced and far more commercially urgent. The question is no longer whether AI can accelerate scientific discovery. The question is whether life sciences organisations can harness real-time data intelligence to connect evidence generation directly to the decisions that determine market access, reimbursement, and commercial success. That connection between living evidence and dynamic market access strategy is where the industry's next major efficiency gains are waiting. And most organisations are not yet equipped to capture them.